Skip to main content
ROHTO PHARMACEUTICAL CO.,LTD. logo

ROHTO PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4527 ISIN · JP3982400008 LEI · 353800Q1CW5OS81OUM12 T Manufacturing
Open in API
Filings indexed 74 across all filing types
Latest filing 2025-04-14 Transaction in Own Shar…
Country JP Japan
Listing T 4527

About ROHTO PHARMACEUTICAL CO.,LTD.

https://www.rohto.co.jp/global/

Rohto Pharmaceutical Co., Ltd. is a multinational company that manufactures and markets a wide range of health and beauty care products. The company's core business areas are over-the-counter (OTC) pharmaceuticals and skincare. It is a recognized leader in the eye care market, particularly known for its extensive line of eye drops. The product portfolio also includes skincare, oral medications, and functional foods. Rohto Pharmaceutical focuses on research and development to create innovative products and services that support the physical and mental well-being of consumers worldwide, aiming to contribute to the future potential of society through health.

Recent filings

Filing Released Lang Actions
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document header explicitly states the filing type as "自己株券買付状況報告書" (Report on the Status of Treasury Stock Acquisition). The legal basis cited is Article 24-6, Paragraph 1 of the Financial Instruments and Exchange Act. The content details the acquisition status of treasury stock (自己株式) during the reporting period (March 1, 2025, to March 31, 2025), including the number of shares acquired and the total value. This specific reporting requirement regarding the company's own share transactions aligns directly with the definition of 'Transaction in Own Shares' (POS), which covers share repurchases.
2025-04-14 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document header explicitly states the filing type as "自己株券買付状況報告書" (Report on the Status of Treasury Stock Acquisition). The legal basis cited is Article 24-6, Paragraph 1 of the Financial Instruments and Exchange Act. The content details the acquisition of treasury stock by the company (ROHTO PHARMACEUTICAL CO., LTD.) during the reporting period (February 1 to February 28, 2025), including the number of shares acquired and the total value, referencing a resolution made by the Board of Directors. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS).
2025-03-14 Japanese
訂正臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau ('関東財務局長'). The '提出理由' (Reason for Submission) explicitly states that the company resolved to issue Euro Yen denominated Convertible Bonds with Stock Acquisition Rights ('ユーロ円建転換社債型新株予約権付社債') and is filing this report based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. This structure and content—detailing the terms of a new debt/equity financing instrument (issuance price, maturity, conversion price, use of proceeds)—are characteristic of a filing related to capital raising activities. This aligns directly with the definition for 'Capital/Financing Update' (CAP). Although it is a formal regulatory filing, the specific nature of the content (issuance of convertible bonds) makes CAP a much more precise classification than the general 'RNS'.
2025-02-27 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) in the header and explicitly states in Section 1 ('提出理由') that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, which corresponds to filings for significant post-closing events that are not covered by standard periodic reports. The content details the resolution by the Board of Directors on February 26, 2025, regarding the issuance of convertible bonds (Euro Yen denominated convertible bonds due 2032) to overseas markets. This type of filing, reporting a major financing/capital structure event outside of the regular 10-K or IR cycle, is best classified as a Capital/Financing Update (CAP). While it is a regulatory filing, 'CAP' is more specific than the fallback 'RNS'. The document length (6287 chars) is substantial, indicating it is the report itself, not just an announcement of a report.
2025-02-26 Japanese
大量保有報告書
Major Shareholding Notification Classification · 100% confidence The document is titled "株券等の大量保有の状況の開示に関する内閣府令 第一号様式 大量保有報告書" (Cabinet Office Ordinance on Disclosure of Status of Large Volume Holding of Share Certificates, etc. Form No. 1 Large Volume Holding Report). This explicitly identifies the document as a Large Volume Holding Report, which in the context of Japanese financial filings, corresponds to a major shareholder notification, typically filed when ownership crosses a certain threshold (often 5% or more). Reviewing the provided definitions, the closest match for a notification of changes in significant share ownership levels is 'Major Shareholding Notification' (Code: MRQ). The document details the holder (ロート製薬株式会社 - Rohto Pharmaceutical Co., Ltd.), the issuer (わかもと製薬株式会社 - Wakamoto Pharmaceutical Co., Ltd.), the number of shares held (3,971,900), and the resulting shareholding percentage (11.40%). This confirms it is a major shareholding disclosure, not a general regulatory filing (RNS) or a report about a meeting (AGM-R).
2025-02-13 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, signed by the CEO and CFO, certifying the accuracy of the company's semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a report (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements. H1 89
2024-11-14 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.